Medicis Pharmaceutical Corp. (MRX) Wednesday reported a decline in profit for the second quarter, due mainly to higher operating expenses.
The Scottsdale, Arizona-based company's second-quarter net profit was $14.93 million or $0.24 per share, compared to $28.78 million or $0.43 per share last year.
Adjusted income for the quarter dropped to $33.29 million or $0.52 per share from $45.99 million or $0.68 per share in the prior-year quarter.
On average, 19 analysts polled by Thomson Reuters expected the company to earn $0.46 per share for the quarter. Analysts' estimates typically exclude special items.
Total revenues for the quarter grew to $196.55 million from $190.83 million in the prior-year quarter. Seventeen analysts had a consensus revenue estimate of $190.96 million for the quarter.
Looking ahead, the company expects third quarter adjusted earnings in the range of $0.41 to $0.58 per share. Revenues for the third quarter are anticipated in the range of $185 million to $200 million. Analysts currently expect the company to earn $0.78 per share for the quarter, with revenues of $221.95 million.
Adjusted earnings for the fourth quarter are expected to range between $0.72 and $0.95 per share. Revenues for the fourth quarter are anticipated in the range of $216 million to $235 million.
The company expects full-year 2012 adjusted net income in the range of $2.25 to $2.65 per share. Revenues for the year are projected in the range of $800 million to $834 million. Analysts currently expect earnings of $2.74 per share for the year, with revenues of $846.41 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.